Skip to main content
. 2020 Jul 10;8:540. doi: 10.3389/fcell.2020.00540

FIGURE 1.

FIGURE 1

MiR-138 treatment decreases the proliferation of lung tumor cells. (A) lent-NC (lent-N, green)/lent-miR-138 (lent-M, green) were administered to nude (left upper panel) or C57BL/6 mice (left bottom panel) bearing corresponding tumor cells (red). After Lent-M treatment, the mean of tumor volume was measured and analyzed (right panel). (B) The expression of Ki67 (green) in tumor tissues from lent-M/lent-N treated A549 tumor bearing mice or non-treated animals. (A,B, eight mice per group were assessed; ***P < 0.001). (C) Flow cytometry detection Ki67 expression on A549 cells, with or without lent-M/lent-N treatment. (D) With, lent-M or lent-N treatment or not, the inhibit ratio of the proliferation of A549 cells were measured by MTT. (E) The amounts of DCs were elevated in tumors from lent-M treated mice compared with the lent-N-treated and untreated groups. (F) Immunofluorescence was used to detect CD11c + cells (green) in tumor tissues from mice treated with lent-M and lent-N, respectively, as well as from untreated animals. The nucleus is blue, Bar = 100 μm. (C–F, three independent assays were performed; ***P < 0.001).